for a number of reasons, such as keeping FT Sites reliable and secure,
personalising content and ads, providing social media features and to
analyse how our Sites are used.
A new world is possible.
Let's not go back to what wasn't working anyway.
Add this topic to your myFT Digest for news straight to your inbox
UK pharma group to commercialise 26 drug targets using technology proven with Covid-19 vaccines
Agency decision to restrict third jabs to vulnerable Americans deals blow to Biden’s strategy
Hedge fund is pushing for chief executive Emma Walmsley to reapply for her job
Joe Biden urges other wealthy countries to follow suit in a bid to boost access around the world
The availability of gene-editing tools such as Crispr has led to an explosion of unchecked DIY experiments in self-built labs
Companies say data provide ‘strong foundation’ to seek authorisation to vaccinate 5-11 age group
Value of labs and campuses soar after pandemic sparked greater interest in sector
Israeli start-up MeMed aims to cut unnecessary prescribing of antibiotics with 15-minute procedure
Advisory committee endorses third dose only for elderly and at-risk groups in blow to Biden
Chief of Serum Institute criticises ‘unethical’ behaviour of wealthy nations pursuing Covid booster jabs
Even with good disclosures and determination, cutting carbon emissions is hard
Analysts predict revenues from Covid-19 jabs will fall precipitously by 2024
Data come as US regulator weighs approval for booster shot to bolster immunity
Bill to allow US government to negotiate lower medicine prices for elderly people fails to advance
Several pharma groups are hoping the Covid vaccine race will turn out to be a marathon, not a sprint
Executive signals intention to secure authorisation for infants as young as six months old
Britain is joining nine other countries that have announced similar programmes offering an additional jab